[1] |
MARANHÃO R C,CARVALHO P O,STRUNZ C C,et al. Lipoprotein(a):structure,pathophysiology and clinical implications[J]. Arq Bras Cardiol,2014,103(1):76-84.
|
[2] |
KAMSTRUP P R,TYBJAERG-HANSEN A,NORDESTGAARD B G.Extreme lipoprotein(a)levels and improved cardiovascular risk prediction[J]. J Am Coll Cardiol,2013,61(11):1146-1156.
|
[3] |
KOSCHINSKY M L,BEISIEGEL U,HENNE-BRUNS D,et al.Apolipoprotein(a)size heterogeneity is related to variable number of repeat sequences in its mRNA[J]. Biochemistry,1990,29(3):640-644.
|
[4] |
WHITE A L,LANFORD R E.Cell surface assembly of lipoprotein(a)in primary cultures of baboon hepatocytes[J]. J Biol Chem,1994,269(46):28716-28723.
|
[5] |
RADER D J,CAIN W,IKEWAKI K,et al.The inverse association of plasma lipoprotein(a)concentrations with apolipoprotein(a)isoform size is not due to differences in Lp(a)catabolism but to differences in production rate[J]. J Clin Invest,1994,93(6):2758-2763.
|
[6] |
WHITE A L,RAINWATER D L,LANFORD R E.Intracellular maturation of apolipoprotein(a)and assembly of lipoprotein(a)in primary baboon hepatocytes[J]. J Lipid Res,1993,34(3):509-517.
|
[7] |
RAAL F J,GIUGLIANO R P,SABATINE M S,et al.Reduction in lipoprotein(a)with PCSK9 monoclonal antibody evolocumab(AMG 145):a pooled analysis of more than 1 300 patients in 4 phase Ⅱ trials[J]. J Am Coll Cardiol,2014,63(13):1278-1288.
|
[8] |
ALONSO R,ANDRES E,MATA N,et al.Lipoprotein(a)levels in familial hypercholesterolemia:an important predictor of cardiovascular disease independent of the type of LDL receptor mutation[J]. J Am Coll Cardiol,2014,63(19):1982-1989.
|
[9] |
FRISCHMANN M E,KRONENBERG F,TRENKWALDER E,et al.In vivo turnover study demonstrates diminished clearance of lipoprotein(a)in hemodialysis patients[J]. Kidney Int,2007,71(10):1036-1043.
|
[10] |
MIKOLASEVIC I,ŽUTELIJA M,MAVRINAC V,et al.Dyslipidemia in patients with chronic kidney disease:etiology and management[J]. Int J Nephrol Renovasc Dis,2017,10:35-45.
|
[11] |
MCNEAL C J.Lipoprotein(a):its relevance to the pediatric population[J]. J Clin Lipidol,2015,9(5 Suppl):S57-S66.
|
[12] |
GUAN W,CAO J,STEFFEN B T,et al.Race is a key variable in assigning lipoprotein(a)cutoff values for coronary heart disease risk assessment:the multi-ethnic study of atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2015,35(4):996-1001.
|
[13] |
BOERWINKLE E,LEFFERT C C,LIN J,et al.Apolipoprotein(a)gene accounts for greater than 90% of the variation in plasma lipoprotein(a)concentrations[J]. J Clin Invest,1992,90(1):52-60.
|
[14] |
MOOSER V,SCHEER D,MARCOVINA S M,et al.The Apo(a)gene is the major determinant of variation in plasma Lp(a)levels in African Americans[J]. Am J Hum Genet,1997,61(2):402-417.
|
[15] |
KRAFT H G,LINGENHEL A,KÖCHL S,et al. Apolipoprotein(a)kringle Ⅳ repeat number predicts risk for coronary heart disease[J]. Arterioscler Thromb Vasc Biol,1996,16(6):713-719.
|
[16] |
KAMSTRUP P R,TYBJAERG-HANSEN A,STEFFENSEN R,et al.Genetically elevated lipoprotein(a)and increased risk of myocardial infarction[J]. JAMA,2009,301(22):2331-2339.
|
[17] |
DUMITRESCU L,GLENN K,BROWN-GENTRY K,et al.Variation in LPA is associated with Lp(a)levels in three populations from the third national health and nutrition examination survey[J]. PLoS One,2011,6(1):e16604.
|
[18] |
LANKTREE M B,ANAND S S,YUSUF S,et al.Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a)in South Asians,Chinese,and European Caucasians[J]. Circ Cardiovasc Genet,2010,3(1):39-46.
|
[19] |
DEO R C,WILSON J G,XING C,et al.Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a)levels in African Americans[J]. PLoS One,2011,6(1):e14581.
|
[20] |
LI J,LANGE L A,SABOURIN J,et al.Genome- and exome-wide association study of serum lipoprotein(a)in the Jackson Heart Study[J]. J Hum Genet,2015,60(12):755-761.
|
[21] |
MARCOVINA S M,KOSCHINSKY M L,ALBERS J J,et al.Report of the national heart,lung,and blood institute workshop on lipoprotein(a)and cardiovascular disease:recent advances and future directions[J]. Clin Chem,2003,49(11):1785-1796.
|
[22] |
TSIMIKAS S,HALL J L.Lipoprotein(a)as a potential causal genetic risk factor of cardiovascular disease:a rationale for increased efforts to understand its pathophysiology and develop targeted therapies[J]. J Am Coll Cardiol,2012,60(8):716-721.
|
[23] |
BERG K,DAHLÉN G,FRICK M H. Lp(a)lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease[J]. Clin Genet,1974,6(3):230-235.
|
[24] |
CATAPANO A L,GRAHAM I,DE BACKER G,et al.2016 ESC/EAS guidelines for the management of dyslipidaemias[J]. Kardiol Pol,2016,74(11):1234-1318.
|
[25] |
TSIMIKAS S.A test in context:lipoprotein(a):diagnosis,prognosis,controversies,and emerging therapies[J]. J Am Coll Cardiol,2017,69(6):692-711.
|
[26] |
KRONENBERG F.Human genetics and the causal role of lipoprotein(a)for various diseases[J]. Cardiovasc Drugs Ther,2016,30(1):87-100.
|
[27] |
NSAIBIA M J,MAHMUT A,BOULANGER M C,et al.Autotaxin interacts with lipoprotein(a)and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease[J]. J Intern Med,2016,280(5):509-517.
|
[28] |
KAMSTRUP P R,NORDESTGAARD B G.Lipoprotein(a)concentrations,isoform size,and risk of type 2 diabetes:a mendelian randomisation study[J]. Lancet Diabetes Endocrinol,2013,1(3):220-227.
|
[29] |
SANTOS R D,RAAL F J,CATAPANO A L,et al.Mipomersen,an antisense oligonucleotide to apolipoprotein B-100,reduces lipoprotein(a)in various populations with hypercholesterolemia:results of 4 phase Ⅲ trials[J]. Arterioscler Thromb Vasc Biol,2015,35(3):689-699.
|
[30] |
TSIMIKAS S,VINEY N J,HUGHES S G,et al.Antisense therapy targeting apolipoprotein(a):a randomised,double-blind,placebo-controlled phase 1 study[J]. Lancet,2015,386(10002):1472-1483.
|